Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paleologos, N. A.
Right arrow Articles by Cairncross, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Paleologos, N. A.
Right arrow Articles by Cairncross, J. G.
Neurology 1999;53:1141
© 1999 American Academy of Neurology
Brief Communications

Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma

Nina A. Paleologos, MD, David R. Macdonald, MD, Nicholas A. Vick, MD and J. Gregory Cairncross, MD

From the Division of Neurology, Evanston Hospital (Drs. Paleologos and Vick), Evanston, IL; and the London Regional Cancer Centre (Drs. Macdonald and Cairncross), London, Ontario, Canada.

Address correspondence and reprint requests to Dr. Nina A. Paleologos, Division of Neurology, Evanston Hosptial, 2650 Ridge Avenue, Evanston, IL 60201.

The authors reviewed the results of neoadjuvant (preradiation) procarbazine, CCNU, and vincristine chemotherapy for anaplastic oligodendrogliomas because, increasingly, chemotherapy is prescribed before radiation for oligodendroglial neoplasms. The data indicate that 70% of patients respond to neoadjuvant chemotherapy, whereas 30% require early radiation because they either have chemoresistant tumors or experience unacceptable chemotoxicity.

Key words: Oligodendroglioma—Chemotherapy—Neoadjuvant.




This article has been cited by other articles:


Home page
 Neuro Oncol DukeHome page
L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al.
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
Neuro-oncol, April 1, 2006; 8(2): 183 - 188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Hoffman, J. M. Propp, and B. J. McCarthy
Temporal trends in incidence of primary brain tumors in the United States, 1985-1999
Neuro-oncol, January 1, 2006; 8(1): 27 - 37.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
K. K. Koeller and E. J. Rushing
From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation
RadioGraphics, November 1, 2005; 25(6): 1669 - 1688.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al.
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M.J. van den Bent, M.J.B. Taphoorn, A.A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J.M. Kros, C.C.D. van der Rijt, Ch.J. Vecht, et al.
Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971
J. Clin. Oncol., July 1, 2003; 21(13): 2525 - 2528.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
Neuro-oncol, April 1, 2003; 5(2): 128 - 138.
[Abstract] [PDF]

Home page
 Ann OncolHome page
M. J. van den Bent, O. Chinot, W. Boogerd, J. Bravo Marques, M. J. B. Taphoorn, J. M. Kros, C. C. D. van der Rijt, C. J. Vecht, N. De Beule, and B. Baron
Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972
Ann. Onc., April 1, 2003; 14(4): 599 - 602.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M.J. van den Bent, F. Keime-Guibert, A.A. Brandes, M.J.B. Taphoorn, J.M. Kros, F.A.L.M. Eskens, and A.F. Carpentier
Temozolomide chemotherapy in recurrent oligodendroglioma
Neurology, July 24, 2001; 57(2): 340 - 342.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
P. J. Jukich, B. J. McCarthy, T. S. Surawicz, S. Freels, and F. G. Davis
Trends in incidence of primary brain tumors in the United States, 1985-1994
Neuro-oncol, July 1, 2001; 3(3): 141 - 151.
[Abstract] [PDF]

Home page
 JCOHome page
O.-L. Chinot, S. Honore, H. Dufour, M. Barrie, D. Figarella-Branger, X. Muracciole, D. Braguer, P.-M. Martin, and F. Grisoli
Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy
J. Clin. Oncol., May 1, 2001; 19(9): 2449 - 2455.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
L. M. DeAngelis
Brain Tumors
N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123.
[Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
N. D. Doolittle, C. P. Anderson, W. A. Bleyer, J. G. Cairncross, T. Cloughesy, S. L. Eck, P. Guastadisegni, W. A. Hall, L. L. Muldoon, S. J. Patel, et al.
Importance of dose intensity in neurooncology clinical trials: Summary Report of the Sixth Annual Meeting of the Blood-Brain Barrier Disruption Consortium
Neuro-oncol, January 1, 2001; 3(1): 46 - 54.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by AAN Enterprises, Inc.